Our findings revealed the downregulation of LINC01133 in ER+ breast cancer and provided novel insight to the role of METTL3/YTHDF2/LINC01133/IGF2BP2 axis in ER+ breast cancer, which might offer a novel perspective in the design and development of novel anticancer drugs. The gene discussed is METTL3; the disease is breast cancer.